testosterone undecanoate has been researched along with Cardiovascular Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Doros, G; Haider, A; Haider, KS; Saad, F | 1 |
| Gilowski, W; Krysiak, R; Okopien, B | 1 |
| Kim, JY; Park, JK; Shin, YS; Zhang, LT | 1 |
| Doros, G; Haider, A; Haider, KS; Rosano, GM; Saad, F; Yassin, A | 1 |
| Almehmadi, Y; Nettleship, JE; Salman, M; Yassin, AA | 1 |
| Agledahl, I; Brodin, E; Hansen, JB; Svartberg, J | 1 |
| Aversa, A; Bruzziches, R; Francomano, D; Isidori, AM; Lenzi, A; Rosano, G; Spera, G | 1 |
1 review(s) available for testosterone undecanoate and Cardiovascular Diseases
| Article | Year |
|---|---|
[Hypogonadism and cardiovascular diseases in men].
Topics: Androgens; Cardiovascular Diseases; Humans; Hypogonadism; Male; Testosterone | 2011 |
2 trial(s) available for testosterone undecanoate and Cardiovascular Diseases
| Article | Year |
|---|---|
Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels.
Topics: Aged; Antigens; Cardiovascular Diseases; Case-Control Studies; Delayed-Action Preparations; Double-Blind Method; Factor VII; Follow-Up Studies; Humans; Hypogonadism; Injections, Intramuscular; Lipids; Lipoproteins; Male; Middle Aged; Risk Factors; Testosterone; Thrombin; Thrombophilia; Thromboplastin; Time Factors | 2009 |
Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Topics: Androgens; Atherosclerosis; Blood Glucose; Blood Pressure; Body Composition; Cardiovascular Diseases; Double-Blind Method; Humans; Hypogonadism; Male; Metabolic Syndrome; Middle Aged; Risk Factors; Testosterone; Waist Circumference | 2010 |
5 other study(ies) available for testosterone undecanoate and Cardiovascular Diseases
| Article | Year |
|---|---|
Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from
Topics: Aged; Anthropometry; Blood Pressure; Cardiovascular Diseases; Humans; Hypogonadism; Injections; Lipids; Longitudinal Studies; Male; Middle Aged; Mortality; Obesity; Overweight; Registries; Testosterone; Weight Loss | 2020 |
The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Fenofibrate; Humans; Hypogonadism; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Risk Factors; Testosterone | 2015 |
Could Testosterone Replacement Therapy in Hypogonadal Men Ameliorate Anemia, a Cardiovascular Risk Factor? An Observational, 54-Week Cumulative Registry Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Androgens; Anemia; Cardiovascular Diseases; Hormone Replacement Therapy; Humans; Hypogonadism; Male; Middle Aged; Registries; Risk Factors; Testosterone; Time Factors; Young Adult | 2016 |
Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Germany; Health Status; Heart Rate; Hormone Replacement Therapy; Humans; Hypogonadism; Lipids; Male; Middle Aged; Recurrence; Registries; Secondary Prevention; Testosterone; Time Factors; Treatment Outcome; Waist Circumference; Weight Loss | 2016 |
Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Aging; Androgens; Body Mass Index; Body Weight; Cardiovascular Diseases; Erectile Dysfunction; Follow-Up Studies; Humans; Hypogonadism; Male; Middle Aged; Obesity; Prospective Studies; Quality of Life; Reproductive Health; Risk Factors; Surveys and Questionnaires; Testosterone; Waist Circumference; Young Adult | 2017 |